TCR-transduced T cell therapy (Providence Health & Services)

N/A

Report date: 2024/11/07 11:09:04

Base Information

Drug NameTCR-transduced T cell therapy (Providence Health & Services)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProvidence Health & Services
China Registration ClassN/A

Develop Information

Active CompaniesProvidence Health & Services
Inactive CompaniesN/A
Active IndicationsCarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A